Antagonism of inhibitor of apoptosis proteins increases bone metastasis via unexpected osteoclast activation

Cancer Discovery

Volumn 3, Issue 2, 2013, Pages 212-223

  Yang, Chang ^a   Davis, Jennifer L ^a   Zeng, Rong ^a   Vora, Paras ^a   Su, Xinming ^b   Collins, Lynne I ^c   Vangveravong, Suwanna ^c   Mach, Robert H ^c   Piwnica Worms, David ^c,d   Weilbaecher, Katherine N ^b   Faccio, Roberta ^e   Novack, Deborah Veis ^a,f  

^a Divisions of Bone and Mineral Diseases   (United States)

^b Divisions of Molecular Oncology   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Departments of Cell Biology and Physiology/BRIGHT Institute   (United States)

^e Departments Orthopedic Surgery   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA3 INTEGRIN; BV 6; CALCITONIN RECEPTOR; INHIBITOR OF APOPTOSIS PROTEIN; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MASS; BONE METASTASIS; BONE TURNOVER; CELL DEATH; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPOROSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; DIPHOSPHONATES; HUMANS; IMIDAZOLES; INHIBITOR OF APOPTOSIS PROTEINS; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; MOLECULAR STRUCTURE; OLIGOPEPTIDES; OSTEOCLASTS; OSTEOPOROSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84873915595     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-12-0271     Document Type: Article

References (45)

1. Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer 2011; 11: 411-25.
2. Suva LJ, Washam C, Nicholas RW, Griffin RJ. Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol 2011; 7: 208-18.
3. Canon JR, Roudier M, Bryant R, Morony S, Stolina M, Kostenuik PJ, et al. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 2008; 25: 119-29.
4. Hiraga T, Williams PJ, Ueda A, Tamura D, Yoneda T. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 2004; 10: 4559-67.
5. Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, et al. Randomized active-controlled phase II study of denosumab effi-cacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007; 25: 4431-7.
6. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a rand-omized, double-blind study. J Clin Oncol 2010; 28: 5132-9.
7. Novack DV, Yin L, Hagen-Stapleton A, Schreiber RD, Goeddel DV, Ross FP, et al. The IκB function of NF-κB2 p100 controls stimulated osteoclastogenesis. J Exp Med 2003; 198: 771-81.
8. Vaira S, Johnson T, Hirbe AC, Alhawagri M, Anwisye I, Sammut B, et al. RelB is the NF-κB subunit downstream of NIK responsible for osteoclast differentiation. Proc Natl Acad Sci U S A 2008; 105: 3897-902.
9. Vallabhapurapu S, Karin M. Regulation and function of NF-κB transcription factors in the immune system. Annu Rev Immunol 2009; 27: 693-733.
10. Sun SC. Non-canonical NF-kappaB signaling pathway. Cell Res 2011; 21: 71-85.
11. Vallabhapurapu S, Matsuzawa A, Zhang W, Tseng PH, Keats JJ, Wang H, et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-κB signaling. Nat Immunol 2008; 9: 1364-70.
12. Zarnegar BJ, Wang Y, Mahoney DJ, Dempsey PW, Cheung HH, He J, et al. Noncanonical NF-κB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat Immunol 2008; 9: 1371-8.
13. Sasaki Y, Calado DP, Derudder E, Zhang B, Shimizu Y, Mackay F, et al. NIK overexpression amplifies, whereas ablation of its TRAF3-binding domain replaces BAFF:BAFF-R-mediated survival signals in B cells. Proc Natl Acad Sci U S A 2008; 105: 10883-8.
14. Yang C, McCoy K, Davis JL, Schmidt-Supprian M, Sasaki Y, Faccio R, et al. NIK stabilization in osteoclasts results in osteoporosis and enhanced inflammatory osteolysis. PLoS ONE 2010; 5: e15383.
15. Aya K, Alhawagri M, Hagen-Stapleton A, Kitaura H, Kanagawa O, Novack DV. NF-κB-inducing kinase controls lymphocyte and osteoclast activities in inflammatory arthritis. J Clin Invest 2005; 115: 1848-54.
16. Varfolomeev E, Goncharov T, Fedorova AV, Dynek JN, Zobel K, Deshayes K, et al. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor α (TNFα)-induced NF-κB activation. J Biol Chem 2008; 283: 24295-9.
17. Mahoney DJ, Cheung HH, Mrad RL, Plenchette S, Simard C, Enwere E, et al. Both cIAP1 and cIAP2 regulate TNFα-mediated NF-κB activa-tion. Proc Natl Acad Sci U S A 2008; 105: 11778-83.
18. Reed JC. Drug insight: cancer therapy strategies based on restora-tion of endogenous cell death mechanisms. Nat Clin Pract Oncol 2006; 3: 388-98.
19. Mannhold R, Fulda S, Carosati E. IAP antagonists: promising candi-dates for cancer therapy. Drug Discov Today 2010; 15: 210-9.
20. Gyrd-Hansen M, Meier P. IAPs: from caspase inhibitors to modu-lators of NF-kappaB, inflammation and cancer. Nat Rev Cancer 2010; 10: 561-74.
21. Weisberg E, Kung AL, Wright RD, Moreno D, Catley L, Ray A, et al. Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. Mol Cancer Ther 2007; 6: 1951-61.
22. Ziegler DS, Wright RD, Kesari S, Lemieux ME, Tran MA, Jain M, et al. Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins. J Clin Invest 2008; 118: 3109-22.
23. Abbas S, Abu-Amer Y. Dominant-negative IκB facilitates apop-tosis of osteoclasts by tumor necrosis factor-α. J Biol Chem 2003; 278: 20077-82.
24. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, et al. IAP antagonists target cIAP1 to induce TNFα-dependent apoptosis. Cell 2007; 131: 682-93.
25. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kaya-gaki N, Garg P, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-κB activation, and TNFα-dependent apoptosis. Cell 2007; 131: 669-81.
26. Vince JE, Wong WW, Gentle I, Lawlor KE, Allam R, O'Reilly L, et al. Inhibitor of apoptosis proteins limit RIP3 kinase-dependent inter-leukin-1 activation. Immunity 2012; 36: 215-27.
27. Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D, et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 2004; 64: 8604-12.
28. Varfolomeev E, Alicke B, Elliott JM, Zobel K, West K, Wong H, et al. X chromosome-linked inhibitor of apoptosis regulates cell death induction by proapoptotic receptor agonists. J Biol Chem 2009; 284: 34553-60.
29. Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, Ho P, et al. A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis 1999; 17: 163-70.
30. Sun H, Nikolovska-Coleska Z, Yang CY, Qian D, Lu J, Qiu S, et al. Design of small-molecule peptidic and nonpeptidic Smac mimetics. Acc Chem Res 2008; 41: 1264-77.
31. Lopez M, Welsh K, Yuan H, Stonich D, Su Y, Garcia X, et al. Antago-nists of IAP-family anti-apoptotic proteins-probe 2. Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda, MD: National Center for Biotechnology Information (US); 2010 [updated 2011 Feb 10].
32. Yarilina A, Xu K, Chen J, Ivashkiv LB. TNF activates calcium-nuclear factor of activated T cells (NFAT)c1 signaling pathways in human macrophages. Proc Natl Acad Sci U S A 2011; 108: 1573-8.
33. Mucci I, Legitimo A, Compagnino M, Consolini R, Migliaccio P, Metelli MR, et al. The methodological approach for the generation of human dendritic cells from monocytes affects the maturation state of the resultant dendritic cells. Biologicals 2009; 37: 288-96.
34. Yin L, Wu L, Wesche H, Arthur CD, White JM, Goeddel DV, et al. Defective lymphotoxin-β receptor-induced NF-κB transcriptional activity in NIK-deficient mice. Science 2001; 291: 2162-5.
35. Hirbe AC, Uluckan O, Morgan EA, Eagleton MC, Prior JL, Piwnica-Worms D, et al. Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner. Blood 2007; 109: 3424-31.
36. Onishi T, Hayashi N, Theriault RL, Hortobagyi GN, Ueno NT. Future directions of bone-targeted therapy for metastatic breast cancer. Nat Rev Clin Oncol 2010; 7: 641-51.
37. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98: 1735-44.
38. Novack DV, Teitelbaum SL. The osteoclast: friend or foe? Annu Rev Pathol 2008; 3: 457-84.
39. Pantel K, Alix-Panabieres C, Riethdorf S. Cancer micrometastases. Nat Rev Clin Oncol 2009; 6: 339-51.
40. Takeshita S, Kaji K, Kudo A. Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. J Bone Miner Res 2000; 15: 1477-88.
41. McHugh KP, Hodivala-Dilke K, Zheng MH, Namba N, Lam J, Novack D, et al. Mice lacking β3 integrins are osteosclerotic because of dys-functional osteoclasts. J Clin Invest 2000; 105: 433-40.
42. Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, et al. Estrogen prevents bone loss via estrogen receptor α and induc-tion of Fas ligand in osteoclasts. Cell 2007; 130: 811-23.
43. Mbalaviele G, Dunstan CR, Sasaki A, Williams PJ, Mundy GR, Yoneda T. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metas-tasis model. Cancer Res 1996; 56: 4063-70.
44. Gross S, Piwnica-Worms D. Real-time imaging of ligand-induced IKK activation in intact cells and in living mice. Nat Methods 2005; 2: 607-14.
45. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meu-nier PJ, et al. Bone histomorphometry: standardization of nomencla-ture, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987; 2: 595-610.